If the tolerogenic effects of IL-2 on Treg production require TGF-β (5), then a TGF-β deficiency could contribute to the lack of efficacy observed in lupus clinical trials involving IL-2. The gene discussed is TGFB1; the disease is systemic lupus erythematosus.